Answer
Monoamine oxidase inhibitors reduce clearance of Suvexx’s sumatriptan component, significantly increasing systemic exposure, so Suvexx is contraindicated during their use and for two weeks after stopping them.
Sources for this answer
- Suvexx 85 mg/457 mg film-coated tabletsOrion Pharma (UK) Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 5Document updated
Sources checked